Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism

Jeffrey A. Kline, Michael A. Puskarich, Jonathan W. Pike, John Zagorski, Nathan J. Alves

Research output: Contribution to journalArticle

Abstract

Background: We test if inhaled nitric oxide (NO) attenuates platelet functional and metabolic hyper-reactivity in subjects with submassive pulmonary embolism (PE). Methods: Participants with PE were randomized to either 50 ppm NO + O2 or O2 only for 24 h with blood sampling at enrollment and after treatment; results were compared with healthy controls. Platelet metabolic activity was assessed by oxygen consumption (basal and uncoupled) and reactivity was assessed with agonist-stimulated thromboelastography (TEG) and fluorometric measurement of agonist-stimulated cytosolic [Ca++] without and with pharmacological soluble guanylate (sGC) modulation. Results: Participants (N = 38 per group) were well-matched at enrollment for PE severity, comorbidities as well as TEG parameters and platelet O2 consumption. NO treatment doubled the mean plasma [NO3-] (P < 0.001) indicating successful delivery, but placebo treatment produced no change. After 24 h, neither TEG nor O2 consumption parameters differed significantly between treatment groups. Platelet cytosolic [Ca++] was elevated with PE versus controls, and was decreased by treatment with cinaciguat (an sGC activator), but not riociguat (an sGC stimulator). Stimulated platelet lysate sGC activity was increased with PE compared with controls. Conclusions: In patients with acute submassive PE, despite evidence of adequate drug delivery, inhaled NO had no major effect on platelet O2 consumption or agonist-stimulated parameters on TEG. Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca++], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target.

Original languageEnglish (US)
Pages (from-to)20-28
Number of pages9
JournalNitric Oxide - Biology and Chemistry
Volume96
DOIs
StatePublished - Mar 1 2020

Fingerprint

Platelets
Pulmonary Embolism
Nitric Oxide
Blood Platelets
Thrombelastography
Therapeutics
Pharmacology
Drug delivery
Oxygen Consumption
Comorbidity
Blood
Chemical activation
Placebos
Modulation
Oxygen
Sampling
Plasmas
Pharmaceutical Preparations

Keywords

  • Blood platelets
  • Comorbidity
  • Humans
  • Nitric oxide
  • Oxygen consumption
  • Platelet activation
  • Pulmonary embolism
  • Pyrazoles
  • Pyrimidines
  • Riociguat
  • Thrombelastography

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Clinical Biochemistry
  • Cancer Research

Cite this

Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism. / Kline, Jeffrey A.; Puskarich, Michael A.; Pike, Jonathan W.; Zagorski, John; Alves, Nathan J.

In: Nitric Oxide - Biology and Chemistry, Vol. 96, 01.03.2020, p. 20-28.

Research output: Contribution to journalArticle

@article{37775ade3fb1495096aeefe90e1b6df0,
title = "Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism",
abstract = "Background: We test if inhaled nitric oxide (NO) attenuates platelet functional and metabolic hyper-reactivity in subjects with submassive pulmonary embolism (PE). Methods: Participants with PE were randomized to either 50 ppm NO + O2 or O2 only for 24 h with blood sampling at enrollment and after treatment; results were compared with healthy controls. Platelet metabolic activity was assessed by oxygen consumption (basal and uncoupled) and reactivity was assessed with agonist-stimulated thromboelastography (TEG) and fluorometric measurement of agonist-stimulated cytosolic [Ca++] without and with pharmacological soluble guanylate (sGC) modulation. Results: Participants (N = 38 per group) were well-matched at enrollment for PE severity, comorbidities as well as TEG parameters and platelet O2 consumption. NO treatment doubled the mean plasma [NO3-] (P < 0.001) indicating successful delivery, but placebo treatment produced no change. After 24 h, neither TEG nor O2 consumption parameters differed significantly between treatment groups. Platelet cytosolic [Ca++] was elevated with PE versus controls, and was decreased by treatment with cinaciguat (an sGC activator), but not riociguat (an sGC stimulator). Stimulated platelet lysate sGC activity was increased with PE compared with controls. Conclusions: In patients with acute submassive PE, despite evidence of adequate drug delivery, inhaled NO had no major effect on platelet O2 consumption or agonist-stimulated parameters on TEG. Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca++], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target.",
keywords = "Blood platelets, Comorbidity, Humans, Nitric oxide, Oxygen consumption, Platelet activation, Pulmonary embolism, Pyrazoles, Pyrimidines, Riociguat, Thrombelastography",
author = "Kline, {Jeffrey A.} and Puskarich, {Michael A.} and Pike, {Jonathan W.} and John Zagorski and Alves, {Nathan J.}",
year = "2020",
month = "3",
day = "1",
doi = "10.1016/j.niox.2020.01.004",
language = "English (US)",
volume = "96",
pages = "20--28",
journal = "Nitric Oxide - Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Inhaled nitric oxide to control platelet hyper-reactivity in patients with acute submassive pulmonary embolism

AU - Kline, Jeffrey A.

AU - Puskarich, Michael A.

AU - Pike, Jonathan W.

AU - Zagorski, John

AU - Alves, Nathan J.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Background: We test if inhaled nitric oxide (NO) attenuates platelet functional and metabolic hyper-reactivity in subjects with submassive pulmonary embolism (PE). Methods: Participants with PE were randomized to either 50 ppm NO + O2 or O2 only for 24 h with blood sampling at enrollment and after treatment; results were compared with healthy controls. Platelet metabolic activity was assessed by oxygen consumption (basal and uncoupled) and reactivity was assessed with agonist-stimulated thromboelastography (TEG) and fluorometric measurement of agonist-stimulated cytosolic [Ca++] without and with pharmacological soluble guanylate (sGC) modulation. Results: Participants (N = 38 per group) were well-matched at enrollment for PE severity, comorbidities as well as TEG parameters and platelet O2 consumption. NO treatment doubled the mean plasma [NO3-] (P < 0.001) indicating successful delivery, but placebo treatment produced no change. After 24 h, neither TEG nor O2 consumption parameters differed significantly between treatment groups. Platelet cytosolic [Ca++] was elevated with PE versus controls, and was decreased by treatment with cinaciguat (an sGC activator), but not riociguat (an sGC stimulator). Stimulated platelet lysate sGC activity was increased with PE compared with controls. Conclusions: In patients with acute submassive PE, despite evidence of adequate drug delivery, inhaled NO had no major effect on platelet O2 consumption or agonist-stimulated parameters on TEG. Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca++], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target.

AB - Background: We test if inhaled nitric oxide (NO) attenuates platelet functional and metabolic hyper-reactivity in subjects with submassive pulmonary embolism (PE). Methods: Participants with PE were randomized to either 50 ppm NO + O2 or O2 only for 24 h with blood sampling at enrollment and after treatment; results were compared with healthy controls. Platelet metabolic activity was assessed by oxygen consumption (basal and uncoupled) and reactivity was assessed with agonist-stimulated thromboelastography (TEG) and fluorometric measurement of agonist-stimulated cytosolic [Ca++] without and with pharmacological soluble guanylate (sGC) modulation. Results: Participants (N = 38 per group) were well-matched at enrollment for PE severity, comorbidities as well as TEG parameters and platelet O2 consumption. NO treatment doubled the mean plasma [NO3-] (P < 0.001) indicating successful delivery, but placebo treatment produced no change. After 24 h, neither TEG nor O2 consumption parameters differed significantly between treatment groups. Platelet cytosolic [Ca++] was elevated with PE versus controls, and was decreased by treatment with cinaciguat (an sGC activator), but not riociguat (an sGC stimulator). Stimulated platelet lysate sGC activity was increased with PE compared with controls. Conclusions: In patients with acute submassive PE, despite evidence of adequate drug delivery, inhaled NO had no major effect on platelet O2 consumption or agonist-stimulated parameters on TEG. Pharmacological activation, but not stimulation, of sGC effectively decreased platelet cytosolic [Ca++], and platelet sGC activity was increased with PE, confirming the viability of sGC as a therapeutic target.

KW - Blood platelets

KW - Comorbidity

KW - Humans

KW - Nitric oxide

KW - Oxygen consumption

KW - Platelet activation

KW - Pulmonary embolism

KW - Pyrazoles

KW - Pyrimidines

KW - Riociguat

KW - Thrombelastography

UR - http://www.scopus.com/inward/record.url?scp=85077913839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077913839&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2020.01.004

DO - 10.1016/j.niox.2020.01.004

M3 - Article

C2 - 31940502

AN - SCOPUS:85077913839

VL - 96

SP - 20

EP - 28

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

SN - 1089-8603

ER -